RNAx and Nucleis announce a collaboration to co-market in vitro and in vivo shRNA target validation technology

08-Sep-2005

Nucleis, a biotechnological company focused on the creation of custom made transgenic mice, and RNAx announced the signing of a non-exclusive co-marketing agreement.

Under the terms of the agreement RNAx provides Nucleis and its customers with in vitro shRNA validation technology to complement their proprietary transgenic animal generation technology, including the "Speedy Mouse® Technology" and vice versa. The goal of the agreement is to provide both RNAx' and Nucleis' customers with both technologies from one source. Financial details of the agreement were not disclosed.

RNAx over the past years has developed a robust automated platform for the customized, rapid and cost effective validation of siRNAs, shRNAs and genetic targets in a broad variety of commonly used cell lines and primary cells, making the screening, selection and functional validation of si- and shRNAs affordable, even at high numbers of targets. Through a number of partnerships with leading European biotech companies, RNAx makes RNAi technology available to many applications during the target discovery and validation process - all the way from gene expression analysis to in vivo validation of more advanced targets.

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics